Key to insitro’s approach to rethinking drug development is the use of cutting edge machine learning to model the space of cell states in health and disease. To enable that, we produce high-quality, high throughput, genomic data of iPSC-derived cellular disease models under genetic and chemical perturbation. We integrate this data with patient genotypes and clinical and molecular phenotypes to identify molecular targets for impactful therapeutics.
As a Genomic Data Scientist, you will develop and apply cutting edge methods to analyze multi-dimensional, multi-modality genomic data to uncover new disease biology. You will work with high quality functional genomic data, such as single-cell RNA-seq, of cells from diverse genetic backgrounds under multiple genetic and chemical perturbations. You will work closely with a cross-functional team of life scientists, bioengineers and machine learning scientists to design and analyze in-house experiments. You will integrate genomic data with other data modalities, such as microscopy and genetics, to investigate iPSC-derived cellular models of various diseases. Finally, you will analyze data from human cohorts and combine it with our in-house results to identify therapeutic targets and develop drugs that have high efficacy and low toxicity.
You will be joining an agile and fast growing biotech startup that has long-term stability due to significant funding. You will have ample opportunities for significant impact. You will work closely with a very talented team, learn a broad range of skills, and help shape insitro’s culture, strategic direction, and outcomes. Join us, and help make a difference to patients!
Nice to Have
Benefits at insitro
insitro is a data-driven drug discovery and development company using machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company is applying state-of-the-art technologies from bioengineering to create massive data sets that enable the power of modern machine learning methods to be brought to bear on key bottlenecks in pharmaceutical R&D. The resulting predictive models are used to accelerate target selection, to design and develop effective therapeutics, and to inform clinical strategy. insitro was launched in 2018 with a Series A of $100M funded by top investors including a16z, Arch Venture Partners, Foresite Capital, GV, and Third Rock Ventures.
The company has announced collaborations with Gilead Sciences in the area of NASH (2019) and Bristol Myers Squibb in the area of ALS (2020) and, in mid 2020, completed a Series B financing of $143M including current investors and new investors Canada Pension Plan Investment Board (CPP Investments), T. Rowe Price, BlackRock, Casdin Capital and other leading investors. The company is located in South San Francisco, CA. For more information about insitro, please visit the company’s website at www.insitro.com
Your application was submitted successfully.